1.
S Afr Med J
; 107(1): 28-30, 2016 Dec 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28112085
RESUMO
Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.